Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
Artikel i vetenskaplig tidskrift, 2019

Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of karyotype aberrations in leukemic cells. Post-hoc analyses of phase III trial data suggested that HDC/IL-2 is primarily beneficial for patients with AML of normal karyotype. These results may be helpful in the selection of patients who are suitable for therapy and in the design of future immunotherapy protocols aiming at further defining the mechanism of relapse prevention by HDC/IL-2.

IL-2

relapse prevention

histamine dihydrochloride

normal karyotype

immunotherapy

Acute myeloid leukemia

Författare

Malin S. Nilsson

Göteborgs universitet

Alexander Hallner

Göteborgs universitet

Mats Brune

Göteborgs universitet

Staffan Nilsson

Chalmers, Matematiska vetenskaper, Tillämpad matematik och statistik

Göteborgs universitet

Fredrik B Thorén

Göteborgs universitet

Anna Martner

Göteborgs universitet

Kristoffer Hellstrand

Göteborgs universitet

Human Vaccines and Immunotherapeutics

2164-5515 (ISSN) 2164-554X (eISSN)

Vol. In Press

Ämneskategorier

Immunologi inom det medicinska området

Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci)

Mikrobiologi inom det medicinska området

DOI

10.1080/21645515.2019.1636598

PubMed

31242079

Mer information

Senast uppdaterat

2019-12-02